Beam Therapeutics’ (BEAM) “Outperform” Rating Reaffirmed at Wedbush
Wedbush reaffirmed their outperform rating on shares of Beam Therapeutics (NASDAQ:BEAM – Free Report) in a research note issued to investors on Monday,RTT News reports. Wedbush currently has a $57.00 target price on the stock. BEAM has been the subject of a number of other research reports. Cantor Fitzgerald upgraded Beam Therapeutics from a “neutral” […]
Wedbush reaffirmed their outperform rating on shares of Beam Therapeutics (NASDAQ:BEAM – Free Report) in a research note issued to investors on Monday,RTT News reports. Wedbush currently has a $57.00 target price on the stock. BEAM has been the subject of a number of other research reports. Cantor Fitzgerald upgraded Beam Therapeutics from a “neutral” […]
